These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 16264875)
41. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
42. Treatment of mantle cell lymphoma: current approach and future directions. Brody J; Advani R Crit Rev Oncol Hematol; 2006 Jun; 58(3):257-65. PubMed ID: 16751087 [TBL] [Abstract][Full Text] [Related]
44. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Habermann TM; Lossos IS; Justice G; Vose JM; Wiernik PH; McBride K; Wride K; Ervin-Haynes A; Takeshita K; Pietronigro D; Zeldis JB; Tuscano JM Br J Haematol; 2009 May; 145(3):344-9. PubMed ID: 19245430 [TBL] [Abstract][Full Text] [Related]
45. Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma. Hess G; Flohr T; Kolbe K; Bonn S; Schuler M; Derigs HG; Huber C Ann Hematol; 2006 Nov; 85(11):769-79. PubMed ID: 16896912 [TBL] [Abstract][Full Text] [Related]
46. Mantle cell lymphoma in the orbital and adnexal region. Rasmussen P; Sjö LD; Prause JU; Ralfkiaer E; Heegaard S Br J Ophthalmol; 2009 Aug; 93(8):1047-51. PubMed ID: 19429588 [TBL] [Abstract][Full Text] [Related]
47. Lenalidomide plus Rituximab for Mantle-Cell Lymphoma. Tsuda K; Tanimoto T; Komatsu T N Engl J Med; 2016 Feb; 374(8):792-3. PubMed ID: 26933863 [No Abstract] [Full Text] [Related]
48. Lenalidomide plus Rituximab for Mantle-Cell Lymphoma. Ruan J; Leonard JP N Engl J Med; 2016 Feb; 374(8):793. PubMed ID: 26933862 [No Abstract] [Full Text] [Related]
49. Activity of thalidomide and lenalidomide in mantle cell lymphoma. Richardson SJ; Eve HE; Copplestone JA; Dyer MJ; Rule SA Acta Haematol; 2010; 123(1):21-9. PubMed ID: 19907157 [TBL] [Abstract][Full Text] [Related]
50. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. Sebban C; Brice P; Delarue R; Haioun C; Souleau B; Mounier N; Brousse N; Feugier P; Tilly H; Solal-Céligny P; Coiffier B J Clin Oncol; 2008 Jul; 26(21):3614-20. PubMed ID: 18559872 [TBL] [Abstract][Full Text] [Related]
51. Fourth biannual report of the Cochrane Haematological Malignancies Group. Kober T; Hülsewede H; Bohlius J; Engert A J Natl Cancer Inst; 2006 Apr; 98(8):E1. PubMed ID: 16622111 [No Abstract] [Full Text] [Related]
52. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. Pönisch W; Rozanski M; Goldschmidt H; Hoffmann FA; Boldt T; Schwarzer A; Ritter U; Rohrberg R; Schwalbe E; Uhlig J; Zehrfeld T; Schirmer V; Haas A; Kreibich U; Niederwieser D; Br J Haematol; 2008 Oct; 143(2):191-200. PubMed ID: 18752593 [TBL] [Abstract][Full Text] [Related]
53. Rituximab-induced severe acute thrombocytopenia: a case report and review of literature. Dhand S; Bahrain H Cancer Invest; 2008 Nov; 26(9):913-5. PubMed ID: 19034773 [TBL] [Abstract][Full Text] [Related]
54. Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma? Ferreri AJ; Dognini GP; Govi S; Crocchiolo R; Bouzani M; Bollinger CR; D'Incan M; Delaporte E; Hamadani M; Jardin F; Martusewicz-Boros M; Montanari M; Szomor A; Zucca E; Cavalli F; Ponzoni M J Clin Oncol; 2008 Nov; 26(31):5134-6; author reply 5136-7. PubMed ID: 18838697 [No Abstract] [Full Text] [Related]
56. Serum sickness following treatment with rituximab. Todd DJ; Helfgott SM J Rheumatol; 2007 Feb; 34(2):430-3. PubMed ID: 17295433 [TBL] [Abstract][Full Text] [Related]
57. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386 [TBL] [Abstract][Full Text] [Related]
58. Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved? Dreyling M; Hiddemann W Curr Opin Oncol; 2008 Sep; 20(5):487-94. PubMed ID: 19106649 [TBL] [Abstract][Full Text] [Related]
59. Concurrent involved field radiation therapy and temsirolimus in refractory mantle cell lymphoma (MCL). Kirova YM; Chargari C; Amessis M; Vernant JP; Dhedin N Am J Hematol; 2010 Nov; 85(11):892. PubMed ID: 20721889 [No Abstract] [Full Text] [Related]